Prophylactic HPV vaccines: new interventions for cancer control (Q37241351)

19 August 2017

1 reference

title

Prophylactic HPV vaccines: new interventions for cancer control (English)

1 reference

19 August 2017

1 reference

Eliav Barr

1

1 reference

PubMed ID

18694795

19 August 2017

Heather L Sings

series ordinal

2

1 reference

PubMed ID

18694795

19 August 2017

language of work or name

English

0 references

publication date

9 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

26

1 reference

19 August 2017

6244-6257

1 reference

19 August 2017

49

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

19 August 2017

1 reference

Epidemiology of Hepatocellular Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus and cervical cytology in adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Trends in the incidence of invasive and in situ vulvar carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Epidemiology of Genital Human Papillomavirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Spontaneous regression of vulvar intraepithelial neoplasia 2-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Vaginal intraepithelial neoplasia: biologic aspects and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Natural history of vaginal intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

External genital warts: diagnosis, treatment, and prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Sexually transmitted infection as a cause of anal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus vaccines and prevention of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

New technologies in cervical cancer precursor detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Epidemiology of genital human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Condylomata acuminata (genital warts): patient demographics and treating physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Development and duration of human papillomavirus lesions, after initial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus infection and intraepithelial, in situ, and invasive carcinoma of penis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

The prevalence of human papillomavirus genotypes in penile cancers from northern Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Recurrent respiratory papillomatosis in children: masquerader of common respiratory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

High incidence of cervical human papillomavirus infection in women during their first sexual relationship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Papillomavirus is resistant to desiccation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Adolescent and young adult women's misunderstanding of the term Pap smear

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus and the value of screening: young women's knowledge of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Awareness of human papillomavirus among women attending a well woman clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

HPV communication: review of existing research and recommendations for patient education

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

The health care costs of cervical human papillomavirus--related disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

The estimated direct medical cost of sexually transmitted diseases among American youth, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

The health and economic burden of genital warts in a set of private health plans in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Progress in prophylactic and therapeutic vaccines for human papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Delivering on the promise: HPV vaccines and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Papillomavirus vaccines in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Preventative and therapeutic vaccines for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Efficacy and other milestones for human papillomavirus vaccine introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Longitudinal evaluation of interobserver and intraobserver agreement of cervical intraepithelial neoplasia diagnosis among an experienced panel of gynecologic pathologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

2001 Consensus Guidelines for the management of women with cervical cytological abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Natural history of cervical neoplasia: defining progression and its consequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Immune responses to human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Improving vaccines by incorporating immunological coadjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Quadrivalent human papillomavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.056

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.07.056

1 reference

19 August 2017

1 reference

PubMed ID

18694795